Valuation: Black Diamond Therapeutics, Inc.

Market Cap 98.27M 85.36M 79.27M 73.1M 138M 9.38B 140M 938M 367M 4.66B 369M 361M 15.67B P/E 2026 *
-2.65x
P/E 2027 * -1.71x
Enterprise Value 98.27M 85.36M 79.27M 73.1M 138M 9.38B 140M 938M 367M 4.66B 369M 361M 15.67B EV / Sales 2026 *
17.7x
EV / Sales 2027 * -
Free-Float
99.35%
Yield 2026 *
-
Yield 2027 * -
1 day+3.31%
1 week-6.79%
Current month-7.30%
1 month-7.30%
3 months-35.28%
6 months-31.12%
Current year-29.42%
1 week 1.64
Extreme 1.64
1.84
1 month 1.64
Extreme 1.64
2.22
Current year 1.6
Extreme 1.6
3.97
1 year 1.6
Extreme 1.6
4.94
3 years 1.2
Extreme 1.195
7.66
5 years 1.18
Extreme 1.18
10.47
10 years 1.18
Extreme 1.18
46.25
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 51 2021-08-10
Chief Executive Officer 62 2023-09-15
Director of Finance/CFO 41 2024-10-06
Director TitleAgeSince
Director/Board Member 61 2017-02-28
Director/Board Member 47 2019-11-30
Director/Board Member 49 2018-11-30
Date Insider Type Main position Quantity % Market Cap.
3/20/26 Free

Director

6,919 0.0121%
1/21/26 Free

Chief Technology Officer

250,000 0.4388%
1/21/26 Free

Founder

250,000 0.4388%
Change 5-day change 1-year change 3-year change Capi.($)
+3.31%-6.79%-39.18%-52.36% 98.27M
-0.81%-0.33%+27.15%+81.12% 55.23B
+2.17%-5.12%+28.40%+67.00% 53.75B
-0.11%+0.86%-15.63%-13.56% 23.48B
-1.58%-5.51%-3.51%+375.36% 22B
+2.49%-0.92%+20.31%-12.15% 19.78B
+0.57%-1.62%+28.56%-33.69% 17.44B
+0.58%-5.88%+16.30%+540.37% 14.66B
+1.16%+0.58%+51.87%+181.96% 14.07B
-5.09%-10.87%+153.11%+272.20% 13.02B
Average +0.27%-2.32%+26.74%+140.63% 23.35B
Weighted average by Cap. +0.23%-0.45%+27.57%+125.09%

Financials

2026 *2027 *
Net sales 5.56M 4.83M 4.48M 4.13M 7.78M 530M 7.93M 53.05M 20.77M 263M 20.86M 20.41M 886M -
Net income -40.47M -35.15M -32.65M -30.11M -56.71M -3.86B -57.74M -386M -151M -1.92B -152M -149M -6.45B -70.04M -60.84M -56.5M -52.11M -98.15M -6.69B -99.93M -669M -262M -3.32B -263M -257M -11.17B
Net Debt - -
Logo Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. It is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.
Employees
21
Date Price Change Volume
26-07-30 $1.715 +3.31% 536,441
26-07-29 $1.660 -5.68% 870,139
26-07-28 $1.760 +1.73% 1,059,311
26-07-27 $1.730 -1.70% 625,209
26-07-24 $1.760 -4.35% 623,287
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
1.715USD
Average target price
9.857USD
Spread / Average Target
+474.76%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BDTX Stock